Can omeprazole and metoclopramide (Reglan) be taken simultaneously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Omeprazole and Metoclopramide (Reglan) Be Taken Together?

Yes, omeprazole and metoclopramide can be taken simultaneously—there are no contraindications to their concurrent use, and they may actually complement each other in treating gastroparesis and GERD symptoms.

Evidence Supporting Concurrent Use

The FDA drug labels for both medications do not list each other as contraindications or significant drug interactions 1, 2. The omeprazole label specifically details important drug interactions but does not mention metoclopramide as a concern 2.

In clinical practice, this combination is commonly used and supported by evidence:

  • Research demonstrates that combining omeprazole with metoclopramide can be beneficial, particularly in conditions requiring both acid suppression and gastric motility enhancement 3
  • A study in obstetric anesthesia showed that adding metoclopramide to omeprazole improved outcomes, with 100% treatment success when both were used together versus 87% with omeprazole alone 3

Clinical Rationale for Combination Therapy

These medications work through different mechanisms:

  • Omeprazole reduces gastric acid secretion by inhibiting the proton pump
  • Metoclopramide enhances gastric motility and accelerates gastric emptying

This complementary action makes them particularly useful together for:

  • Gastroparesis with acid-related symptoms
  • GERD refractory to acid suppression alone
  • Conditions requiring both reduced acid production and improved gastric emptying

Critical Safety Considerations for Metoclopramide

While the combination is safe, metoclopramide carries significant risks that require careful monitoring 4, 1:

Black Box Warning - Tardive Dyskinesia

  • Risk increases with duration and dose
  • Maximum treatment duration: 12 weeks 4, 1
  • Higher risk in: older patients, women, and diabetics 4, 1
  • Movements may be irreversible even after stopping the drug 1

Other Serious Adverse Effects

  • Neuroleptic Malignant Syndrome (NMS): rare but life-threatening, requires immediate hospitalization 1
  • Acute dystonia: uncontrolled muscle spasms, typically within first 2 days 1
  • Depression and suicidality: monitor for mood changes 1
  • Parkinsonism: especially problematic in patients with pre-existing Parkinson's disease 1

Dosing Strategy to Minimize Risk

Per AGA guidelines 4:

  • Start with 5 mg before meals, increase to 10 mg if needed
  • Consider 1-4 week drug holidays every 8-12 weeks
  • Assess efficacy and adverse effects at 4-8 weeks
  • Continue monitoring throughout treatment duration

Important Drug Interaction Caveat

While omeprazole and metoclopramide don't interact with each other, be aware of metoclopramide's interactions with other medications 1:

  • MAO inhibitors
  • Medications causing movement disorders (antipsychotics)
  • Sedating medications (may enhance drowsiness)
  • Insulin (dose adjustment may be needed in diabetics)

Similarly, omeprazole has significant interactions that require attention 2:

  • Clopidogrel (avoid concurrent use)
  • Warfarin (monitor INR)
  • Methotrexate (consider temporary withdrawal)
  • Certain antiretrovirals (rilpivirine is contraindicated)

Practical Implementation

When prescribing this combination:

  1. Document clear indication for metoclopramide use
  2. Discuss tardive dyskinesia risk with patient before starting 4
  3. Plan for maximum 12-week course unless compelling reason to continue
  4. Schedule follow-up at 4-8 weeks to assess response and adverse effects 4
  5. Monitor for movement disorders at each visit
  6. Review all other medications for potential interactions with either drug

Common pitfall to avoid: Continuing metoclopramide beyond 12 weeks without reassessment—this significantly increases tardive dyskinesia risk 4, 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.